Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 11Thoracic 3Head & Neck 3Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Other solid neoplasm 1Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 36Head and Neck Neoplasms 19Oropharyngeal Neoplasms 7Recurrence 6Melanoma 6Prostatic Neoplasms 5Carcinoma, Squamous Cell 5Small Cell Lung Carcinoma 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Mouth Neoplasms 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Stomach Neoplasms 2Sarcoma 2Nasopharyngeal Carcinoma 2Lung Neoplasms 2Laryngeal Neoplasms 2Laryngeal Diseases 2Esophageal Squamous Cell Carcinoma 2Turcot syndrome 1

Interventions

pembrolizumab 20Docetaxel 8Carboplatin 8Fluorouracil 6Cisplatin 6Nivolumab 5fludarabine 4Trastuzumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Cyclophosphamide 4Biopsy 4Bevacizumab 4fludarabine phosphate 3durvalumab 3atezolizumab 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Capecitabine 3Albumin-Bound Paclitaxel 3ulixertinib 2tisotumab vedotin 2spartalizumab 2belinostat 2adavosertib 2X-Rays 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Esophageal Neoplasms × durvalumab × Head & Neck × Clear all
NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Active not recruiting
39 enrolled 8 charts
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03212469 2025-05-08

ABIMMUNE

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Completed
54 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡